First publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor program

March 23, 2018
ANTABIO S.A.S

March 23, 2018 - Antabio announces publication of a manuscript in Antimicrobial Agents and Chemotherapy: Discovery of a Novel Metallo-ß-Lactamase Inhibitor, which can Potentiate Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae (currently available as an ePublication – https://www.ncbi.nlm.nih.gov/pubmed/29530861). This is the first publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor program and provides early proof-of-concept for this approach as a way to address the threat to public health from the spread of MBL producing Carbapenem-Resistant Enterobacteriaceae (CRE) pathogens. The paper describes the characterisation of a prototype compound which displays good potentiation of meropenem activity against CRE bacteria, in both in vitro and in vivo studies, combined with promising drug-like properties. Antabio have continued to optimise this series towards candidate selection with a view to entering the clinic in 2019.